Trial · NCT07899905
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
NCT07899905, Phase 4, Not yet recruiting, Merck Sharp & Dohme LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022). Trials, record NCT07899905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899905
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
- NCT number
- NCT07899905
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24. | Baseline and Week 24 | The 6MWD is a clinical test that measures the distance, in meters, that a participant can walk on a flat, hard surface in a period of 6 minutes. This test evaluates the participant's integrated response to exercise (functional capacity). An increase in the distance walked represents an improvement in functional exercise capacity. The change from baseline is calculated by subtracting the baseline distance from the Week 24 distance. |
| Primary | Number of Participants Who Experience an Adverse Event (AE) | Up to approximately 37 weeks. | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported. |
| Primary | Number of Participants Who Discontinue Study Treatment Due to an AE | Up to approximately 21 weeks. | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
| Secondary | Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24 | Baseline and Week 24 | PVR, a hemodynamic variable of pulmonary circulation, is measured by right heart catheterization (RHC). The change from baseline in PVR at Week 24 will be presented. |
| Secondary | Percentage of Participants with Improvement in World Health Organization (WHO) Functional Class (FC) at Week 24 | Baseline and Week 24 | The WHO FC is a 4-category scale (Class I, II, III, or IV) that assesses the severity of a participant's disease based on symptoms and physical limitations. A lower class indicates less severe disease. Improvement is defined as a decrease of at least one functional class from Baseline to Week 24. Maintenance of WHO FC II is defined as remaining in WHO FC II from Baseline to Week 24. The percentage of participants who demonstrate improvement or maintenance of WHO FC II at Week 24 will be reported. |
| Secondary | Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) at Week 24 | Baseline and Week 24 | NT-proBNP is an established marker of ventricular dysfunction in participants with PAH. NT-proBNP will be measured at baseline and at Week 24. The change from baseline in NT-proBNP at Week 24 will be presented. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899905
GET https://conductscience.org/api/trials/v1/NCT07899905/registered